While earnings usually come in substantially ahead of expectations — as much as 4 or 5 percentage points is not unusual — the downward direction in the outlook doesn't speak...Earningsread more
"We do not seek conflict with Iran or any other country," Trump tells reporters in the Oval Office.Politicsread more
Shopify debuts a new network to help it compete with Amazon.Marketsread more
"We missed being the dominant mobile operating system by a very tiny amount. We were distracted during our antitrust trial. We didn't assign the best people to do the work,"...Technologyread more
Sen. Bernie Sanders announced a plan Monday to forgive the country's $1.6 trillion outstanding student loan tab, intensifying the higher education policy debate in the 2020...Personal Financeread more
The strong dollar story could be over for now, and that's putting a shine on the 'anti-dollar' trade—gold.Market Insiderread more
Some traders think the energy rally is about to wane, despite the sector being one of June's big winners.ETF Edgeread more
Stocks with this one feature are poised to crush the market after a rate cut, according to Goldman Sachs.Marketsread more
An Air Canada passenger traveling to Toronto from a weekend in Quebec City found herself stranded alone on the tarmac and in the dark, in what she described as a "nightmare."Airlinesread more
The new cut will likely draw thousands back to theaters and could finally push "Avengers: Endgame" above and beyond the record $2.78 billion "Avatar" has earned since its...Entertainmentread more
"I believe it would be wise to take additional time and allow events to unfold" before deciding on rates, the Dallas Fed official said in an essay.The Fedread more
In a letter to Gilead CEO John Martin, Healey suggested the costs of the two hepatitis C drugs "may constitute an unfair trade practice in violation of Massachusetts law."
"I write to encourage you to reconsider Gilead's pricing structure for Sovaldi and Harvoni ... so that we may actually see this infectious disease eradicated in the United States in our lifetime," she wrote, adding that her office will "continue to examine this potential claim for unfair commercial conduct."
A full course of Sovaldi currently goes for $84,000, and a 12-week Harvoni treatment costs $94,500.
Healey wrote in her letter date Friday that that if Massachusetts were to purchase Sovaldi at its retail price for all of the people with hepatitis C in the state's prisons, then the costs would "easily exceed" the entire budget for prisoner health care.
After word of the price increases for specialty drugs including Sovaldi, Democratic presidential hopeful Hillary Clinton announced she planned take action against skyrocketing drug costs.
Gilead has said it is committed to expand access to its medicines, regardless of ability to pay. The company has said it offers a "support path" for those who may have trouble paying for its therapies.
"We agree with the Attorney General about the importance of helping all HCV patients — and that the advent of safe, effective regimens means we can now consider the possibility of eradicating the disease," a Gilead spokeswoman told CNBC, adding that the company had reached out to Healey about setting up a meeting to discuss the issue.
"We look forward to working with the Attorney General's office to address questions and concerns and ensure a mutual understanding of the work we are doing to deliver a cure for HCV to as many patients as possible in Massachusetts and around the world," she added.
CNBC obtained a copy of Healey's letter after its contents were reported Wednesday by The Boston Globe.
—CNBC's Meg Tirrell contributed to this report.